samedan logo

home > news > detailed info

Eurofins BioPharma Product Testing Columbia supports Plus Therapeutics’ Key RNLTM Development and cGMP Drug Manufacturing

Eurofins BioPharma Product Testing

COLUMBIA, Missouri, May 12, 2021 – Eurofins BioPharma Product Testing Columbia (the “Company”), part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide, today announced a collaboration agreement with Plus Therapeutics, Inc. (“Plus Therapeutics”), a clinical stage pharmaceutical company developing novel, targeted therapies for rare and difficult cancers. The Company will support Plus Therapeutics’ process development and analytical chemistry activities for the cGMP manufacturing of Rhenium NanoLiposome (RNL™), Plus Therapeutics’ lead investigational asset in clinical development for recurrent glioblastoma.

Under the Company’s agreement with Plus Therapeutics, the Company will develop and validate test methods for purity, composition, and identity of Re-BMEDA, the active pharmaceutical ingredient (API) in RNL™. These test methods will support release testing and compliance with cGMP requirements for new drug substances.

“Process optimization and appropriate quality controls of investigational compounds are very critical aspects in bringing novel drugs to markets,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “We have identified a best-in-class partner in Eurofins to help us get one step further in bringing RNL to a registrational clinical trial and ultimately commercial supply."
phone +32 2 766 16 20
email Chaussée de Malines, 455 B-1950 Kraainem
Print this page
Send to a friend
News and Press Releases

Sartorius to Join the DAX Blue Chip Index

September 4, 2021 – The life science group Sartorius will be admitted to the German DAX blue chip index. After the market closes on September 17, 2021, Sartorius preference shares will be included in the calculation of the DAX, as Deutsche Börse announced on Friday evening.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement